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Abstract 
 
This study examined correlates of transient versus persistent psychotic symptoms among 
people dependent on methamphetamine.  A longitudinal prospective cohort study of 
dependent methamphetamine users who did not meet DSM-IV criteria for lifetime 
schizophrenia or mania. Four non-contiguous one-month observation periods were used to 
identify participants who had a) no psychotic symptoms, (n = 110); (b) psychotic symptoms 
only when using methamphetamine (transient psychotic symptoms, n = 85); and, (c) psychotic 
symptoms both when using methamphetamine and when abstaining from methamphetamine 
(persistent psychotic symptoms, n = 37). Psychotic symptoms were defined as a score of 4 or 
greater on any of the Brief Psychiatric Rating Scale items of suspiciousness, hallucinations or 
unusual thought content. Relative to no psychotic symptoms, both transient and persistent 
psychotic symptoms were associated with childhood conduct disorder and comorbid anxiety 
disorders,. Earlier onset methamphetamine use and being male were more specifically related 
to transient psychotic symptoms, while a family history of a primary psychotic disorder and 
comorbid major depression were specifically related to persistent psychotic symptoms. We 
conclude that there are overlapping but also distinct clinical correlates of transient versus 
persistent psychotic symptoms, suggesting potentially heterogeneous etiological pathways 
underpinning the psychotic phenomena seen amongst people who use methamphetamine. 
 
Keywords: street drugs, central nervous system stimulants, amphetamine, amphetamine-
related disorders, psychotic disorders, paranoia, hallucinations 
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1. Introduction 
Methamphetamine (‘crystal meth’ or ‘ice’) is an addictive synthetic stimulant that can 
produce a brief psychotic episode, characterized by persecutory delusions and hallucinations, 
which strongly resembles acute paranoid schizophrenia (Angrist & Gershon, 1970; Bell, 
1973; Griffith, 1970). The risk of psychosis is dose-related, increasing during periods of 
heavy methamphetamine use and receding during periods of abstinence (McKetin et al., 2013) 
and can be exacerbated by premorbid concurrent risk factors for psychosis (e.g. comorbid 
disorder, stress, sleep deprivation)(Bramness et al., 2012; Chen et al., 2003; Glasner-Edwards 
& Mooney, 2014). However, not all people who use methamphetamine experience psychotic 
symptoms (Chen et al., 2003; Hides et al., 2015). Among those who do, most experience a 
transient psychosis that recedes after intoxication from methamphetamine (Chen et al., 2003; 
Schuckit, 2006). A minority of people experience a more prolonged psychosis that persists 
beyond the use of the drug (Akiyama, 2006; Iwanami et al., 1994) and vulnerability to 
recurrent psychotic episodes that can occur in the absence of methamphetamine use (Sato, 
1983). It is unclear whether this persistent psychosis reflects the precipitation of a 
schizophrenia spectrum disorder in vulnerable individuals (Callaghan et al., 2012; Niemi-
Pynttari et al., 2013; Schuckit, 2006) or a chronic form of methamphetamine-induced 
psychosis (Tomiyama, 1990).  
 
Identifying risk factors for methamphetamine-related psychosis, particularly the persistent 
form, is a necessary first step in providing targeted health promotion messages to people who 
use the drug and early interventions for those who may be at risk of developing a chronic 
psychosis. In addition to heavier methamphetamine use (Chen et al., 2003; Degenhardt et al., 
2015; Hall et al., 1996; Lecomte et al., 2013; McKetin et al., 2013; McKetin et al., 2006), 
identified correlates of methamphetamine-related psychosis include initial use at a young age, 
a premorbid schizoid personality, a family history of schizophrenia (Chen et al., 2005; Chen 
et al., 2003; Tsuang et al., 1982) or affective illness (Chen et al., 2005), childhood adversity 
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(Ding et al., 2014) and behavioral problems (Salo et al., 2013), and comorbid mental 
disorders, including major depression, alcohol dependence and antisocial personality disorder 
(Chen et al., 2003; Lecomte et al., 2013).  
 
Less is known about factors that predict the more persistent form of methamphetamine 
psychosis and inconsistent findings have been reported from the few studies that have 
systematically examined correlates of transient versus persistent methamphetamine psychosis. 
On the one hand, persistent psychosis has been associated with greater premorbid risk for 
schizophrenia (Chen et al., 2005; Chen et al., 2003), depression, antisocial personality traits, 
and a longer history of substance use (Lecomte et al., 2013). On the other hand, other studies 
have not found a link between methamphetamine-related psychosis and a premorbid risk for 
schizophrenia (Hides et al., 2015; Lecomte et al., 2013; McKetin et al., 2006), nor have they 
consistently reported on whether risk factors (e.g. depression, substance use history) differ for 
transient versus persistent psychosis (Chen et al., 2005; Chen et al., 2003).   
 
In our past research we utilized a longitudinal study design to understand how 
methamphetamine use increases risk for experiencing psychotic symptoms. Specifically, by 
tracking a cohort of dependent methamphetamine users (who did not meet lifetime DSM-IV 
criteria for schizophrenia or mania), we were able to document a dose-related increase in the 
occurrence of psychotic symptoms during periods of methamphetamine use relative to periods 
of abstinence (McKetin et al., 2013). Although most symptoms of psychosis in this cohort 
were transient, a minority of participants reported psychotic symptoms during periods when 
they were not using the drug, consistent with the notion of a more persistent form of 
methamphetamine psychosis. It was also apparent that, although methamphetamine 
substantially increased the risk of psychotic symptoms, not all people who used the drug 
experienced psychotic symptoms. 
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In this paper, we explore potential clinical and demographic correlates associated with the 
expression of psychotic symptoms in this cohort of dependent methamphetamine users. 
Specifically, we examined whether there were any differences between people who 
experienced psychosis exclusively when using methamphetamine, those who continued to 
experience psychosis when they stopped using the drug, and those who did not experience 
psychotic symptoms at all. 
 
2. Method 
2.1 Participants and procedure 
Participants (N = 278) all met DSM-IV criteria for methamphetamine dependence on entry to 
the study and none met DSM-IV criteria for lifetime schizophrenia or mania. DSM-IV 
diagnoses were assessed using the Composite International Diagnostic Interview (CIDI) 
(Andrews & Peters, 1998).  Participants were from a larger study, the Methamphetamine 
Treatment Evaluation Study (MATES) cohort, which is detailed elsewhere (McKetin et al., 
2012). In brief, the MATES cohort included 400 people entering community-based drug 
treatment services in Sydney and Brisbane, Australia, for methamphetamine use, and 101 
methamphetamine users from Sydney who were not in treatment (i.e., recruited through 
needle and syringe programs and outreach services) but who screened positive for dependence 
on methamphetamine. Other inclusion criteria for MATES were being at least 16 years old, 
comprehension of English, being willing to participate in follow-up interviews, and, not 
having been in methamphetamine treatment, other inpatient drug treatment, or in prison, in 
the month prior to entering the study. These latter exclusion criteria were necessary in 
MATES to obtain a naturalistic baseline measure of drug use.  
 
From the MATES cohort, 17 participants were excluded from the current study because they 
did not meet DSM-IV criteria for methamphetamine dependence on recruitment. A further 59 
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were excluded because they met DSM-IV criteria for either lifetime schizophrenia or a 
lifetime manic episode, and 138 were excluded because this diagnostic information was not 
available (i.e., these participants did not partake in the follow-up interviews when diagnoses 
were made). A further 9 participants were excluded because they had not used 
methamphetamine during any of the one-month observation periods used in the analysis. 
 
A structured interview schedule was administered at baseline and each follow-up (3 months, 1 
year and 3 years after the baseline interview). Recruitment of the cohort took place in 2006 
and 2007, while follow-up interviews spanned the period from 2006 to 2010. Interviews were 
conducted face-to-face or by phone. All participants provided informed consent, were 
volunteers, and were reimbursed for their time and travel expenses (up to AUD40 per 
interview). All of the participants in the current study were re-interviewed at 3 months and 1 
year after entry to the cohort, and 83% (n = 230) were interviewed at 3 years. The current 
study used data on drug use and psychotic symptoms in the past month at each of these four 
time points, totaling 1,064 months of data for all of the participants combined.  
 
The study was approved by the UNSW Human Research Ethics Committee and this 
permission was ratified by all other participating institutions. All participants were volunteers 
who provided informed consent prior to participation and who were reimbursed up to AU$40 
per interview.  
 
2.2 Measures 
2.2.1 Psychotic symptoms: Psychotic symptoms were assessed for the past month and were 
defined as a score of four or greater on any of the Brief Psychiatric Rating Scale (BPRS) 
items of suspiciousness, unusual thought content or hallucinations. BPRS scores of 4+ 
indicate clinically significant or pathological symptom intensity (Lukoff et al., 1986). Ratings 
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were made by trained interviewers (Honours level psychology graduates  or equivalent) and 
weekly meetings were held to review BPRS ratings in order to maintain inter-rater agreement 
and avoid rater drift (Ventura et al., 1993). Inter-rater agreement for the definition of 
psychotic symptoms used in this study was 93%, yielding a kappa of 0.86 (McKetin et al., 
2013).    
 
2.2.2 Methamphetamine use: Days of methamphetamine use in the past four weeks was 
measured using the Opiate Treatment Index (Darke et al., 1992). Self-reported abstinence 
from methamphetamine use was confirmed in a sub-sample of the entire MATES cohort, with 
false reporting of abstinence occurring in only 6% of cases (McKetin et al., 2013). Age of 
first methamphetamine use, route of methamphetamine administration, and severity of 
methamphetamine dependence were assessed at baseline. Severity of methamphetamine 
dependence was assessed using the Severity of Dependence Scale (SDS), a validated five item 
scale that yields a score between 0 and 15, with higher scores reflecting more severe 
dependence (Gossop et al., 1995).  
 
2.2.3 Other drug use measures: Days of use in the past four weeks was measured for 
cannabis, heroin, cocaine, ecstasy, hallucinogens, alcohol, tobacco, benzodiazepines and 
antidepressant medication. Both prescription and non-prescription use of benzodiazepines and 
antidepressant medication were included.   
 
2.2.4 Comorbidity: The CIDI (Andrews & Peters, 1998) was used to make DSM-IV 
diagnoses of methamphetamine dependence and other Axis I psychiatric disorders. Past year 
diagnoses of social phobia, panic disorder and major depression were made at the baseline 
and at the 1 year follow-up interview. A positive diagnosis was based on meeting diagnostic 
criteria at either of these two interviews. A DSM-IV diagnosis of childhood conduct disorder 
was made using a modified version of the Diagnostic Interview Schedule (Robins et al., 
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1982). A history of Attention Deficit Hyperactivity Disorder (ADHD) was based on the 
participant reporting that they had ever been told by a doctor that they had this condition.  
 
2.2.5 Family history of psychotic disorders: A family history of primary psychotic disorder 
was assessed by asking the participant “Has anyone in your family ever been diagnosed with 
a major mental illness, like mania, bipolar disorder, schizophrenia, or other psychosis?” 
Disorders were coded as schizophrenia, mania/bipolar, drug-induced psychosis, and other 
psychosis (e.g., depression with psychotic features, post-partum psychosis). Drug-induced 
psychotic disorders were not included as a primary psychotic disorder. 
 
2.3 Design and statistical analysis 
Data were analyzed using Stata SE version 11.2 (Stata Corporation, 2014). All tests were two-
sided with significance set at p < 0.05.  An initial overall test was conducted to establish 
whether between-group differences existed across the three groups. Follow-up pairwise 
comparisons were conducted to establish which groups differed.  These comparisons were 
made using a Kruskal Wallis test for continuous data (because these data were not normally 
distributed) and a Pearson’s Chi-square test for categorical outcomes. Multivariate 
simultaneous logistic regression was used to adjust for between group differences in severity 
of methamphetamine dependence (SDS score) when comparing the persistent psychotic 
symptom group and no psychotic symptom group on family history of psychosis and 
comorbid depression.  
 
9 
 
3. Results 
3.1 Characteristics of the sample 
Participants (N = 278) had a mean age of 31.7 years (SD = 8.1 years), 72% were male, 89% 
were Australian born and 96% nominated English as their preferred language. All met DSM-
IV criteria for methamphetamine dependence on entry to the study; they had used the drug for 
a mean of 13.1 years (SD = 7.9 years) and 83% had injected it. Methamphetamine use 
occurred during 58% of the observed months (on a median of 8 days, range 1-28 days) with 
injection the main route of administration (79% of months). Other drug use consisted 
primarily of tobacco, alcohol and cannabis (89%, 62% and 57% of months respectively). 
Psychotic symptoms occurred for 25% of all months and 60% of participants reported 
psychotic symptoms during at least 1 month of their follow-up. Further details on the sample 
characteristics and the relationship between methamphetamine use and psychotic symptoms 
are reported elsewhere (McKetin et al., 2013). 
3.2 Transient and persistent psychotic symptoms in the sample 
Participants were divided into three groups according to whether they experienced psychotic 
symptoms: (a) neither during any months when they were using methamphetamine nor during 
any months when they were not using methamphetamine (no psychotic symptoms, n = 110, 
47%); (b) during at least one month when they were using methamphetamine, but not during 
any months when they were not using the drug (transient psychotic symptoms, n = 85, 37%); 
and (c) during at least one month when they were using methamphetamine and also during at 
least one month when they were not using the drug (persistent psychotic symptoms, n = 37, 
16%).  Participants were excluded from these groupings if they had used methamphetamine 
on all of the follow-ups because we could not confirm the absence of psychotic symptoms 
during periods of abstinence from methamphetamine (n = 35) or if they had psychotic 
symptoms only during months of abstinence from methamphetamine (n = 11).  
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3.3 Correlates of vulnerability to psychotic symptoms 
There were overlapping and distinct factors associated with transient versus persistent 
psychotic symptoms (Table 1). Compared to participants who experienced no psychotic 
symptoms, participants reporting transient psychotic symptoms were more likely to have a 
history of conduct disorder and have a comorbid anxiety disorder. Persistent psychotic 
symptoms were similarly associated with conduct disorder and anxiety disorders (being more 
strongly associated with panic disorder than were transient psychotic symptoms).. Persistent 
psychotic symptoms were also associated with major depression and a family history of a 
primary psychotic disorder.  
 
Groups were reasonably comparable in their drug use history on entry to the study, with the 
exception of participants with persistent psychotic symptoms being more severely dependent 
on methamphetamine (Table 1).  The relationship between persistent psychotic symptoms and 
a family history of a psychotic disorder (adjusted OR 2.7, 95% CI 1.1- 6.4, p = 0.026) and 
comorbid depression (adjusted OR 2.8, 95% CI 1.2- 6.8, p = 0.021) remained significant after 
adjusting for severity of methamphetamine dependence.  
 
To investigate whether the use of substances other than methamphetamine contributed to 
persistent psychotic symptoms we examined substance use for months when participants were 
abstaining from methamphetamine (i.e., at risk of persistent psychotic symptoms). Compared 
to participants with no psychotic symptoms, participants with persistent psychotic symptoms 
were more likely to have taken antidepressants (27% vs. 44%, χ2 = 4.3, p = 0.039) and 
benzodiazepines (12% vs. 24%, χ2 = 4.9, p = 0.026) during these months when they were 
abstaining from methamphetamine. There were no other significant group differences in other 
substance use during these months, or during months of methamphetamine use (p > 0.05, 
analyses not shown).  
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Table 1 about here. 
  
12 
 
4. Discussion 
We found different clinical correlates of transient versus persistent psychotic symptoms in 
this otherwise homogeneous sample of dependent methamphetamine users. Although some 
factors were associated with both transient and persistent psychotic symptoms (childhood 
conduct disorder, comorbid anxiety disorders) a family history of a primary psychotic 
disorder, comorbid depression, and more severe dependence on methamphetamine, were 
specifically associated with persistent psychotic symptoms. Both a family history of a primary 
psychotic disorder and comorbid depression remained significantly associated with persistent 
psychotic symptoms after adjusting for severity of methamphetamine dependence. 
  
Our findings are suggestive of potentially distinct but overlapping etiological pathways 
involved in the development of transient versus persistent psychotic symptoms in people who 
use methamphetamine. The disjuncture between predictors of transient and persistent 
psychotic symptoms is consistent with the findings of Tsuang et al., who found that long-
lasting substance-related psychosis was associated with a broader clinical symptom profile 
and different clinical correlates (more premorbid personality disorders, greater familial risk of 
schizophrenia and affective disorders) than brief substance-related psychosis (Tsuang et al., 
1982). Our findings are also consistent with the broader research on psychotic experiences in 
the general population, in that, although there is evidence of a continuum of psychosis and 
related risk factors, there is evidence that there are distinct etiological influences on different 
psychotic experiences (e.g. higher heritability for negative symptoms cf. hallucinations) 
(McGrath et al., 2015; van Os, 2014; Zavos et al., 2014).  
 
The finding that persistent psychotic symptoms were more specifically related to a family 
history of a primary psychotic disorder suggests that these individuals may have a pre-
existing vulnerability to psychosis. Past studies have also found also found greater familial 
risk for schizophrenia among people who experience lasting vs. brief psychosis in the context 
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of methamphetamine use (Chen et al., 2005) and other substance use (Tsuang et al., 1982). 
Taken together, these findings suggest that persistent psychosis may reflect the precipitation 
of schizophrenia, or unmasking of schizophrenia in vulnerable individuals, which may be 
etiologically distinct from the transient psychotic phenomena induced by acute use of the drug 
(Schuckit, 2006).  
 
Our finding that major depression was specifically associated with persistent psychotic 
symptoms is consistent with elevated familial risk for affective disorders among people with 
long-lasting versus brief substance-related psychosis (Tsuang et al., 1982) and lasting 
depressive symptoms seen amongst methamphetamine users who experience persistent 
psychosis (Lecomte et al., 2013). Depression may form an intrinsic symptom of persistent 
methamphetamine psychosis, making it similar to schizoaffective disorder, or an atypical 
schizophrenia (Tsuang et al., 1982), or it could also reflect the affective prodrome seen with 
first episode psychosis (Birchwood, 2003). Comorbid depression could also be a consequence 
of experiencing prolonged psychosis because of the psychological distress caused by ongoing 
psychotic symptoms and the impact that this can have on a person’s day-to-day functioning 
(Birchwood, 2003).  
 
We found a strong relationship between anxiety disorders and both transient and persistent 
psychosis, suggesting that anxiety may play a role in the development of psychotic symptoms 
in methamphetamine users. The elevated prevalence of anxiety disorders, and their interplay 
with psychosis, has been recognized in the context of primary psychotic disorders 
(Birchwood, 2003; Cassano et al., 1998), but has not been documented for methamphetamine 
psychosis. Comorbidity between psychosis and anxiety disorders is likely driven by a bi-
directional effect of paranoia increasing social fear and perception of social criticism, while 
the propensity toward such sensitivities in people with anxiety disorders may fuel paranoia by 
augmenting perceptions of threat (Grezellschak et al., 2015). The development of psychosis 
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could further entrench the social avoidance seen with these disorders because of the stigma 
attached to psychosis and/or fear of other people (Birchwood, 2003). In the context of 
methamphetamine use, symptoms of anxiety and panic are likely to be further exacerbated by 
the physiological effects of stimulant intoxication, those including tachycardia, chest pain and 
sympathetic arousal. Increased recognition of anxiety disorders in people who use 
methamphetamine, and the use of cognitive therapies that target misperceptions of social 
threat (Grezellschak et al., 2015), may be helpful to alleviate both anxiety and the severity of 
psychotic symptoms.  
 
Other correlates of psychotic symptoms were generally consistent with past research. 
Antisocial personality disorder and its childhood precursor, conduct disorder, are recognized 
comorbidities in people with psychotic disorders (Mueser et al., 2006), and our study is one of 
a growing number to identify this link with methamphetamine psychosis (Chen et al., 2003; 
Lecomte et al., 2013; Sulaiman et al., 2014). Although male gender was not significantly 
associated with psychosis risk, this null finding may have been due to lack of statistical 
power.   
 
A limitation of our approach was that we relied on several discrete data collection epochs to 
judge whether participants had transient versus persistent psychotic symptoms. It is possible 
that a proportion of participants experienced persistent psychotic symptoms that were not 
captured within these discrete observation periods. This constraint would have resulted in the 
misclassification of some participants as having transient psychotic symptoms even though 
they may have experienced persistent symptoms. Similarly, a proportion of participants may 
have experienced transient psychotic symptoms, but not at the times that we observed them 
(and hence would have been misclassified as having no psychotic symptoms). This 
misclassification would have reduced our ability to detect differences between groups. 
Therefore, null effects found in this study, particularly where non-significant trends were 
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apparent, should be treated tentatively. The small number of participants classified as having 
persistent psychosis may have also contributed to null findings. Replication of these results in 
a larger cohort would be desirable to confirm null effects. 
 
The relatively small number of participants classified as having a persistent psychotic 
symptoms prevented a more sophisticated modelling of what factors were most predictive of 
persistent versus transient psychosis. Importantly, several of the predictors we examined 
could be spuriously associated with psychosis by virtue of their relationship with comorbid 
conditions (e.g., conduct disorder is more prevalent in males and associated with increased 
prevalence of other mental disorders (Nock et al., 2006)).  Therefore it is not possible to make 
conclusive statements about which factors best predict psychosis compared with those that are 
merely correlates of the condition.  
 
Finally, we only assessed the core symptoms of methamphetamine psychosis (paranoid 
delusions and hallucinations), whereas the broader symptom profile of transient and persistent 
substance-related psychosis have been found to differ (Caton et al., 2006; Tsuang et al., 
1982). It would be helpful in future research to see whether distinct predictors of transient 
versus persistent methamphetamine psychotic symptoms were due to their association with 
specific symptoms that differed between these conditions. For example, Tsuang et al. found 
that long-lasting substance-related psychosis was characterized by more negative symptoms 
(e.g. poor insight, flat affect), greater delusional content, and fewer hallucinations than brief 
substance-related psychosis (Tsuang et al., 1982). Negative symptoms and paranoia have 
higher heritability than hallucinations (Zavos et al., 2014), which might explain why we found 
that persistent psychotic symptoms were more strongly related to family history of a primary 
psychotic disorder. In other words, correlates of transient versus persistent psychotic 
symptoms may reflect the specific symptom profile of these conditions rather than symptom 
duration per se. 
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In summary, our findings emphasize that there are overlapping but also distinct clinical 
correlates of transient versus persistent psychotic symptoms among methamphetamine users, 
suggesting that these entities may be, to some extent, etiologically distinct. This finding is 
consistent with the broader psychosis literature where there is increasing recognition that 
different psychotic experiences/phenotypes may have different etiologies and clinical 
correlates (McGrath et al., 2015). Despite this complexity, many of our findings replicate 
previously identified correlates of methamphetamine psychosis risk. Understanding which 
factors predict a more chronic course of psychosis in methamphetamine users is a critical first 
step in identifying people who may benefit from early intervention to prevent a progression to 
schizophrenia. 
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Table 1. Characteristics of participants by vulnerability to psychotic symptoms 
 No psychotic  
symptoms 
(n = 110) 
Transient 
psychosis 
(n = 85) 
Persistent 
psychosis 
(n =37) 
P value for 
overall test 
Total sample 
(n = 232) 
Male (%) 7 82* 76 .057 74 
Age (median) 31.5 31 31 .361 31 
Immigrant status (%) 7 15 8 .168 10 
Family history of psychotic disorder (%) 15 26 35* .029 22 
Comorbid disorders (%)      
 Conduct disorder 66 85** 84* .006 76 
 Major Depression 55 64 78* .043 63 
 Social Phobia 15 38*** 46*** < .001 29 
 Panic Disorder 18 39** 62***§ < .001 34 
Self-reported ADHD 19 16 11 .504 17 
Methamphetamine use history      
 Age first use (median) 17 16 16 .096 31 
 Years of use (median) 12 11 12 .850 11.5 
Methamphetamine use at baseline      
 SDS score (median) 9 9 11** .016 9 
 Days of use in past month (median) 14 16 15 .282 15 
 Injecting (%) 74 69 73 .800 74 
Other drug usea (%)      
 Tobacco 94 93 89 .663 93 
 Alcohol 74 66 70 .502 70 
 Cannabis 78 81 78 .867 78 
 Ecstasy 22 26 22 .775 24 
 Cocaine 19 26 32 .215 27 
 Heroin 22 22 16 .725 22 
 Other opioids 27 24 22 .731 27 
 Inhalants 8 7 8 .995 7 
 Antidepressants  24 20 22 .830 22 
 Benzodiazepines 35 45 35 .319 41 
* p < 0.05, ** p < 0.01, ***p < 0.001 relative to no psychotic symptoms; § p < 0.05 relative to 
transient psychosis. 
a Other drug use is any use of the drug in the past month at the baseline interview. 
